A new study will investigate the potential effects of CBD on heart function for the first time.
Researchers at Mount Sinai Medical Hospital in New York will examine the effects that CBD may have on cardiology markers in a six-month clinical trial which may prove “groundbreaking” for the field.
The clinical trial consists of two studies conducted by Dr David Harnick, a prominent cardiologist and assistant professor of medicine and cardiology at Mount Sinai Medical Hospital.
It has been constructed to gather data that will help in the deeper understanding of the effects CBD has on the body.
US health and wellness CBD company, HempFusion has announced that its products had been chosen as the exclusive provider by Dr Harnick, who commented: “Studying the potential effects that CBD may have on cardiology markers may potentially unlock some of the scientific mysteries that exist today.
“We know that there is evidence that CBD may have beneficial effects on the body, but the exact scope of those effects remains to be determined. There have been no published randomised prospective controlled trials evaluating the effects of CBD on these cardiac markers, so this research may prove to be groundbreaking.”
The study is expected to commence in March 2021 and it will be one-of-a-kind in the area of the effects of CBD on targeted cardiology markers.
Dr. Harnick chose HempFusion for its rigorous regulatory standards, toxicology studies for safety, and adherence to quality control.
The company also recently partnered with ValidCare as a co-sponsor alongside 12 other companies in the CBD space, collaborated in an industry-wide Human Observational liver and male reproductive toxicology studies, which explore the effects that full-spectrum hemp-derived CBD has on the liver.
“This is the second clinical trial HempFusion is proudly participating in,” HempFusion Wellness CEO Jason Mitchel, N.D. said.
“We are committed to furthering research in the area of hemp-derived CBD and this study [with Dr. Harnick] is a significant expansion of our efforts that reinforces our continued focus on the safe and effective use of hemp-derived CBD products,” he added.
The CBD used in these trials is the same product the company offers to the public.
- The role of the endocannabinoid system in dermatological diseases
- Cannabis may help reduce reliance on other stimulants, finds study
- Greece welcomes ‘new era’ of medical cannabis after seven-year wait
- Spain publishes draft medical cannabis framework, but omits flower
- Broughton: How to design a robust CBD testing strategy
- Medical Cannabis Division of Rokshaw Ltd Rebranding to Curaleaf Laboratories
News5 months ago
FSA drops recommended daily dose of CBD to 10mg – everything you need to know
Pain6 months ago
Medical cannabis ‘effective’ and ‘fast-acting’ for neuropathic pain – study
News4 months ago
UK government accepts ACMD recommendations for CBD products
Industry5 months ago
First UK-grown cannabis medicine expected by end of 2023
News6 months ago
The Netherlands to launch cannabis legalisation pilot December 2023
News6 months ago
BBC documentary highlights ‘pot luck’ of access to cannabis on NHS
Science5 months ago
New cannabis research: cancer, Type 2 diabetes, autism, fibromyalgia and skin disorders
News4 months ago
Europe’s first legal cannabis dispensaries to open under sixth Swiss pilot